Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Hodge Website

James W. Hodge, Ph.D., MBA

Selected Publications

1)  Hodge JW, Sabzevari H, Yafal AG, Gritz L, Lorenz MG, Schlom J.
A triad of costimulatory molecules synergize to amplify T-cell activation.
Cancer Res. 59: 5800-7, 1999.
[Journal]
2)  Gameiro SR, Caballero JA, Higgins JP, Apelian D, Hodge JW.
Exploitation of differential homeostatic proliferation of T-cell subsets following chemotherapy to enhance the efficacy of vaccine-mediated antitumor responses.
Cancer Immunol Immunother. 60: 1227-42, 2011.
[Journal]
3)  Hodge JW, Garnett CT, Farsaci B, Palena C, Tsang K, Ferrone S, Gameiro SR.
Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death.
Int. J. Cancer. 133: 624-36, 2013.
[Journal]
4)  Gameiro SR, Jammeh ML, Wattenberg MM, Tsang KY, Ferrone S, Hodge JW.
Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing.
Oncotarget. 5: 403-16, 2014.
[Journal]
5)  Ardiani A, Farsaci B, Rogers CJ, Protter A, Guo Z, King TH, Apelian D, Hodge JW.
Combination therapy with a second-generation androgen receptor antagonist and a metastasis vaccine improves survival in a spontaneous prostate cancer model.
Clin. Cancer Res. 19: 6205-18, 2013.
[Journal]
6)  Donahue RN, Duncan BB, Fry TJ, Jones B, Bachovchin WW, Kiritsy CP, Lai JH, Wu W, Zhao P, Liu Y, Tsang K, Hodge JW.
A pan inhibitor of DASH family enzymes induces immunogenic modulation and sensitizes murine and human carcinoma cells to antigen-specific cytotoxic T lymphocyte killing: implications for combination therapy with cancer vaccines.
Vaccine. [Epub ahead of print], 2014.
[Journal]
7)  Wattenberg MM, Kwilas AR, Gameiro SR, Dicker AP, Hodge JW.
Expanding the use of monoclonal antibody therapy of cancer by using ionising radiation to upregulate antibody targets.
Br. J. Cancer. 110: 1472-80, 2014.
[Journal]
8)  Campbell CT, Gulley JL, Oyelaran O, Hodge JW, Schlom J, Gildersleeve JC.
Humoral response to a viral glycan correlates with survival on PROSTVAC-VF.
Proc. Natl. Acad. Sci. U.S.A. [Epub ahead of print], 2014.
[Journal]
9)  Gulley JL, Madan RA, Tsang KY, Jochems C, Marté JL, Farsaci B, Tucker JA, Hodge JW, Liewehr DJ, Steinberg SM, Heery CR, Schlom J.
Immune impact induced by PROSTVAC (PSA-TRICOM), a therapeutic vaccine for prostate cancer.
Cancer Immunol Res. 2: 133-41, 2014.
[Journal]
10)  Bernstein MB, Garnett CT, Zhang H, Velcich A, Wattenberg MM, Gameiro SR, Kalnicki S, Hodge JW, Guha C.
Radiation-Induced Modulation of Costimulatory and Coinhibitory T-Cell Signaling Molecules on Human Prostate Carcinoma Cells Promotes Productive Antitumor Immune Interactions.
Cancer Biother. Radiopharm. [Epub ahead of print], 2014.
[Journal]
Click Here to View Expanded Bibliography.

This page was last updated on 6/20/2014.